RenovoRx Inc
RNXT1.220USD
+0.010+0.83%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
44.59MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über RenovoRx Inc Unternehmen
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.
Unternehmensinformationen
BörsenkürzelRNXT
Name des UnternehmensRenovoRx Inc
IPO-datumAug 17, 2021
CEOMr. Shaun R. Bagai
Anzahl der mitarbeiter10
WertpapierartOrdinary Share
GeschäftsjahresendeAug 17
Addresse2570 W. El Camino Real, Ste. 320,
StadtMOUNTAIN VIEW
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl94040
Telefon14088002649
Websitehttps://renovorx.com/
BörsenkürzelRNXT
IPO-datumAug 17, 2021
CEOMr. Shaun R. Bagai
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Ms. Leesa Gentry
Ms. Leesa Gentry
Chief Clinical Officer
Chief Clinical Officer
--
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
Dr. Una S. Ryan, Ph.D.
Dr. Una S. Ryan, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Ronald B. (Ron) Kocak, CPA
Mr. Ronald B. (Ron) Kocak, CPA
Principal Financial Officer and Accounting Officer, Vice President, Controller
Principal Financial Officer and Accounting Officer, Vice President, Controller
--
--
Mr. Shaun R. Bagai
Mr. Shaun R. Bagai
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Ms. Leesa Gentry
Ms. Leesa Gentry
Chief Clinical Officer
Chief Clinical Officer
--
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
AIGH Capital Management, LLC.
7.09%
AWM Investment Company, Inc.
6.25%
The Vanguard Group, Inc.
3.68%
Agah (Ramtin M.D.)
3.10%
Worth Venture Partners, LLC
2.39%
Other
77.49%
Aktionäre
Aktionäre
Anteil
AIGH Capital Management, LLC.
7.09%
AWM Investment Company, Inc.
6.25%
The Vanguard Group, Inc.
3.68%
Agah (Ramtin M.D.)
3.10%
Worth Venture Partners, LLC
2.39%
Other
77.49%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
10.42%
Private Equity
7.09%
Investment Advisor
5.92%
Individual Investor
4.42%
Hedge Fund
3.79%
Bank and Trust
0.27%
Venture Capital
0.06%
Other
68.03%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
51
11.69M
31.97%
+5.32M
2025Q1
52
10.53M
29.46%
+6.73M
2024Q4
39
1.47M
4.14%
-2.25M
2024Q3
38
2.35M
9.16%
-392.19K
2024Q2
40
2.34M
14.23%
-1.80M
2024Q1
36
1.98M
17.38%
-1.99M
2023Q4
40
1.81M
16.91%
-1.93M
2023Q3
39
3.15M
32.01%
-2.10M
2023Q2
36
3.04M
31.03%
-2.11M
2023Q1
36
5.01M
55.46%
+3.39M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
AIGH Capital Management, LLC.
2.59M
7.09%
+2.59M
--
Mar 31, 2025
AWM Investment Company, Inc.
2.29M
6.25%
+2.29M
--
Mar 31, 2025
The Vanguard Group, Inc.
1.35M
3.68%
+1.20M
+851.09%
Mar 31, 2025
Agah (Ramtin M.D.)
1.13M
3.1%
+21.00K
+1.89%
Jun 05, 2025
Worth Venture Partners, LLC
873.61K
2.39%
+873.61K
--
Mar 31, 2025
Alyeska Investment Group, L.P.
688.58K
1.88%
+688.58K
--
Mar 31, 2025
Bleichroeder LP
500.00K
1.37%
+500.00K
--
Mar 31, 2025
Adar1 Capital Management LLC
479.88K
1.31%
+282.63K
+143.29%
Mar 31, 2025
Geode Capital Management, L.L.C.
321.87K
0.88%
+86.13K
+36.53%
Mar 31, 2025
Bagai (Shaun R.)
320.04K
0.88%
+27.50K
+9.40%
Apr 25, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
